Will the last one to leave the building please turn out the lights?
Boston Scientific (BSX) will apparently ax up to 3,400 people. It appears that CEO James Tobin and his co-founders Peter Michael Nicholas, Jr. and John Abele will not be among them. But, they should be.
BSX is a wreck. After buying medical device-maker Guidant for $24 billion, BSX took on a load of debt that it is having trouble paying back According to The Associated Press "Boston Scientific’s credit standing among the three major ratings agencies has recently fallen into junk bond territory, creating pressure to release cost-cutting specifics."
The company’s critical stent business is being hammered by on-going reports that drug-coated stents can cause clots and heart attacks. Cardiologists are shying away from using them and have turned to drug-based treatments instead.
BSX shares were at $27 in December 2005. They are off over 4% today to $14.41.
The company still needs to convince Wall St. that it can pay back all of that money. It could bring in capital by selling shares of Guidant in the public market.
Douglas A. McIntyre
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
